Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06161584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv9
  2. Primary and study completion dates: Jun 2028 to Jun 2027v8
  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 34 of 34 sitesv7 Show 1 more changeShow less
    • Site details revised at 34 of 34 sites
  4. Primary and study completion dates: Oct 2027 to Jun 2028 Study sites: 33 to 34v6 Show 1 more changeShow less
    • Study sites: 33 to 34
  5. Study sites: 32 to 33v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 31 to 32v4
  2. Study sites: 28 to 31v3
  3. Study sites: 1 to 28v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Trial Details
NCT Number NCT06161584
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions Geographic Atrophy
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov